Top News Stories November 16 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 16 2017”

Top News Stories November 14 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 14 2017”

Top News Stories For November 13 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories For November 13 2017”

Top Weekend News Stories November 11 – 12, 2017

The top news stories this weekend from stocks on the GuerillaStockTrading watch list.
Continue reading “Top Weekend News Stories November 11 – 12, 2017”

Abbott Laboratories Gets FDA Clearance for its Alinity

We have been stalking Abbott Laboratories for an entry. With FDA clearance of its Alinity mobile blood test unit and recent pullback, now may be the time for an entry.

Abbott Laboratories gets FDA 510(k) clearance for its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics.

Brian Blaser, Executive Vice President, said, “Healthcare systems across the United States are under pressure to deliver better care for patients. Labs and healthcare systems are looking for complete solutions that help them operate more efficiently while contributing to better clinical decision making and helping improve patient outcomes.”
Continue reading “Abbott Laboratories Gets FDA Clearance for its Alinity”

Abbott Laboratories Stock Higher On Analysts Price Target Hikes

Abbott Laboratories stock is rising fast after reporting earnings. Four analysts reaffirmed or upgraded the stock to a Buy or Outperform rating after Abbott Laboratories earnings report beat on both earnings and revenue.

The company reported earnings of $0.66 versus the $0.65 estimate. Revenue also beat coming in at $6.83 billion versus the $6.72 billion estimate. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. Abbott Laboratories’s revenue for the quarter was up 28.8% on a year-over-year basis.
Continue reading “Abbott Laboratories Stock Higher On Analysts Price Target Hikes”